BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease.

doi:10.1111/gbb.12724

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease.

Genes, brain, and behavior - 1 Jun 2021

Lim Yen Ying, Laws Simon M, Perin Stephanie, Pietrzak Robert H, Fowler Christopher, Masters Colin L, Maruff Paul

Abstract excerpt

The brain-derived neurotrophic factor (BDNF) Val66Met (rs6265) polymorphism has been shown to moderate the extent to which memory decline manifests in preclinical Alzheimer's disease (AD). To date, no study has examined the relationship between BDNF and memory in individuals across biologically confirmed AD clinical stages (i.e., Aβ+). We aimed to understand the effect of BDNF on episodic memory decline and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Alzheimer Disease

Share to Brain-Derived Neurotrophic Factor

Share to Disease Progression

Share to Heterozygote

Share to Memory

Share to Mutation, Missense

Source

Open in PubMed

Identifiers

PMID: 33369083
DOI: 10.1111/gbb.12724

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BDNF VAL66MET polymorphism and memory decline across the spectrum of Alzheimer's disease.PMID 33369083Read ↗

Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study.Semantic proximity Read ↗

BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.Semantic proximity Read ↗

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.Semantic proximity Read ↗

BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention.Semantic proximity Read ↗

BDNF Val66Met moderates increases in CSF t-tau and p-tau181 in early sporadic Alzheimer’s disease: A prospective cohort studySemantic proximity Read ↗

APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.Semantic proximity Read ↗

The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease.Semantic proximity Read ↗

The implication of BDNF Val66Met polymorphism in progression from subjective cognitive decline to mild cognitive impairment and Alzheimer’s disease: a 9-year follow-up studySemantic proximity Read ↗

Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairmentSemantic proximity Read ↗

Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without DementiaSemantic proximity Read ↗

Association of plasma BDNF levels with different stages of Alzheimer's disease: a cross-sectional study.Semantic proximity Read ↗

Synergy effects of HbA1c and variants of APOE and BDNFVal66Met explains individual differences in memory performance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.